Morgan Stanley: Eli Lilly's oral weight loss drug clinical trial data is impressive, maintaining target price at $1,028

2025-09-18 14:58:22

Morgan Stanley's research report stated that Eli Lilly's oral GLP-1 receptor agonist Orfor has performed well in weight loss, improvement of cardiovascular metabolic indicators and safety. The newly released data has not changed its positive view on Orfor's prospects. It maintains an "overweight" rating and a target price of US$1,028 in the next 12 months.

weight loss drug Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    HGTECH's 3.2T NPO products are used by leading industry customers
                            2025-09-24

                                    Alipay's two operating entities have completed the name change
                            2025-09-19